"Centro médico de asistencia e investigación"

During the past decade, CER Instituto Medico conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 23 clinical trials were completed, i.e. on average, 76.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 20 clinical trials were completed. i.e. 222.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CER Instituto Medico" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Celgene" with 5 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Galapagos NV" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CER Instituto Medico" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "OCT Clinical Trials" with 2 trials as a collaborator and "Parexel" with 2 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "CER Instituto Medico" are "Rheumatoid Arthritis" (10 trials), "Ulcerative Colitis" (9 trials), "Systemic Lupus Erythematosus" (3 trials), "Chemotherapy-Induced Nausea and Vomiting" (2 trials) and "Colitis, Ulcerative" (2 trials). Many other conditions were trialed in "CER Instituto Medico" in a lesser frequency.

Most popular intervention types in "CER Instituto Medico" are "Drug" (36 trials), "Other" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Baricitinib" (3 trials), "Etanercept" (3 trials), "Filgotinib" (3 trials) and "Adalimumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "CER Instituto Medico" are 37 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CER Instituto Medico". undefined are not yet recruiting, 6 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in CER Instituto Medico, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in CER Instituto Medico, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".